

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61F 2/06</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/30564</b>
		(43) International Publication Date: 2 June 2000 (02.06.00)

(21) International Application Number: <b>PCT/US99/27504</b>	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 19 November 1999 (19.11.99)	
(30) Priority Data: 60/109,526 23 November 1998 (23.11.98) US 09/434,071 5 November 1999 (05.11.99) US	
(71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue NE, Minneapolis, MN 55432 (US).	
(72) Inventors: ZILLA, Peter, Paul; 14 Dal Road, 8005 Camps Bay (ZA). BEZUIDENHOUT, Deon; 2 Liebenhoff, Merriman Avenue, 7600 Stellenbosch (ZA).	Published <i>Without international search report and to be republished upon receipt of that report.</i>
(74) Agents: DUTHLER, Reed, A. et al.; Medtronic, Inc., 7000 Central Avenue NE, Minneapolis, MN 55432 (US).	

(54) Title: POROUS SYNTHETIC VASCULAR GRAFTS WITH ORIENTED INGROWTH CHANNELS



## (57) Abstract

A vascular prosthesis is constructed from a structure having interconnected, helically oriented channel-porosity to allow oriented ingrowth of connective tissue into a wall of the prosthesis. The prosthesis can have a small internal diameter of 6 mm or less. Several different methods can be used to produce the prosthesis, including a fiber winding and extraction technique, a melt extrusion technique, and a particle and fiber extraction technique using either a layered method or a continuous method. Furthermore, mechanical properties of the prosthesis are matched with mechanical properties of the host vessel, thereby overcoming problems of compliance mismatch.

INT'L PCT PUBLICATIONS  
IN THE UNITED STATES

PCT/2004/102

The International Bureau of the World Intellectual Property Organization (WIPO) has issued a circular letter to all Contracting States of the Patent Cooperation Treaty (PCT) regarding the publication of international applications under the PCT.

The letter states that the United States Patent and Trademark Office (USPTO) will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

PCT/2004/102

The letter states that the United States Patent and Trademark Office (USPTO) will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

The letter also states that the USPTO will begin publishing international applications under the PCT on January 1, 2005.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	NX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## POROUS SYNTHETIC VASCULAR GRAFTS WITH ORIENTED INGROWTH CHANNELS

### FIELD OF THE INVENTION

This invention is directed to a vascular prosthesis having oriented channel-porosity to allow for oriented ingrowth of connective tissue into a wall of the prosthesis. Furthermore, mechanical properties of the prosthesis are matched with mechanical properties of a host vessel, thereby overcoming problems of compliance mismatch.

### BACKGROUND OF THE INVENTION

Vascular disease in small to medium diameter arteries adversely affects arterial wall structure. As a result, blood flow through the vessel is hindered either by total occlusion or, in the opposite extreme, an acute over dilation of the vessel (aneurysm). Such indications usually require reconstructive or bypass surgery. The most successful replacements at present are autologous grafts (arteries and veins taken from the host), but often these are too diseased or unsuitable for use as an implant. There is thus a great need for the development of a reliable small diameter vascular prosthesis. Over the last 40 years, considerable progress has been made in the development of arterial prostheses. The modern era of vascular surgery began in the early 1950's, 40 years after Carrel and Gutherie (1906) demonstrated that autologous veins could be used to replace arteries. With the advent of antibiotics and anticoagulants in ancillary medicine, the development of vascular prostheses prospered. The reversed saphenous vein was soon considered the best artery replacement and was used successfully in femoral artery replacement by Kunlin in 1949. However, the need for a smaller prosthesis led to further research by Gross and associates involving homografts using sterilized tissue. Although early results were encouraging, the long-term results were still unsatisfactory, with the grafts often failing due to thrombosis and aneurysm.

While pioneers such as Gross et al. (1948) continued to work on hetero- and homografts, Voorhees made an important observation in 1952 that changed the direction of vascular prosthetic development. After discovering that cells grew on silk thread exposed to blood, he showed the effectiveness of synthetic textile or fabric tubes as arterial replacements. A new era of vascular surgery began and the search for the most suitable material and optimal structure for a textile graft began.

Experiments, even recently, have investigated factors such as knitted or woven textiles, large or small pores, different surface finishes and crimping and external reinforcing.

Presently, the materials used for vascular implants are tanned natural vessels, textile tubes made from woven or knitted Dacron, or tubes made from expanded polytetrafluoroethylene (e-PTFE). These grafts are successful for large diameter artery replacement where there is a high blood flow rate; but they have a much lower success rate in arteries with a diameter less than 6 mm. These conventional prosthetic vascular grafts do not permit unrestricted vessel ingrowth from the surrounding tissue due mostly to ingrowth spaces that are either too narrow or discontinuous. All of the present grafts eventually fail by occlusion due to thrombosis (fibrous tissue build up), or intimal hyperplasia (exuberant muscle growth at the interface between artery and graft).

Factors such as the thrombogenic nature of the graft material, surface roughness, the mechanical and haemodynamic properties of the graft and the condition of the host artery are known to influence the success of the graft. Although the reasons for failure are not fully understood, it is largely agreed that compliance mismatch between artery and graft is the predominant issue surrounding the failure of small diameter prostheses. Discontinuity in mechanical properties between the graft and artery alters the blood flow resulting in a fibrous tissue build-up leading to the complete occlusion and hence failure of the graft.

One of the main reasons for a fibrous build up on the graft is the thrombogenic reaction of the blood with the graft material. Much of the current research involves the development of various polymers, especially polyurethanes, to which biological coatings can be applied to improve the stability of the graft in the body over long periods. Ideally the graft should have an endothelial cell lining on the inner wall.

This prevents a reaction by providing a less thrombogenic flow surface for the blood passing through it. One way of achieving this is through a porous graft structure. This, in conjunction with suitable biological engineering, can induce cell ingrowth through the wall leading to musculogenesis and the eventual endothelialization of the inner surface.

Autologous grafts, such as the saphenous vein and the internal mammary artery are still considered the best grafts for the reconstruction of small peripheral arteries, but these are often too diseased or unsuitable for use as a graft. None of the present textile grafts (e-PTFE and Dacron) have proved successful for long periods.

Many approaches to graft production have been developed in an effort to create a porous polyurethane artery graft. Indeed, it has been shown that it is possible to create an initially compliant porous graft. However, the long-term success of such grafts remains to be proven. It has become apparent that the current methods of graft construction are ineffectual and a new approach is necessary.

It is evident that the present small diameter grafts do not provide an acceptable long-term patency. Although the causes for failure are not immediately clear, it is apparent that none of the previous prostheses have the same structure as an artery or behave mechanically as an artery does. Apart from the biological issues, which are arguably the most important and complex issues in graft design, one of the central issues involves understanding the mechanics of arterial behavior. Recent investigations have addressed the issue of compliance in an effort to create a structurally similar graft, but compliance alone has not proved completely successful. Thus, there is a need to develop a graft that addresses the issue of mechanical behavior through structure. The graft structure should create an optimal strain environment that will facilitate and encourage the development and maintenance of endothelial and smooth muscle cells in the vessel.

#### SUMMARY OF THE INVENTION

The present invention is directed to a synthetic vascular graft with helically oriented, interconnected transmural ingrowth channels. Vascular tissues are mostly helically arranged in the walls of natural arteries. This invention allows for helically oriented ingrowth of connective tissue into walls of synthetic graft prostheses in order to simulate mechanical properties of natural vessels.

Several different methods can be used to produce the graft of the present invention. In one method, a tube is fashioned from a graft material by coating an extractable fiber with a solution containing a biocompatible material including the graft material, and then winding the fiber onto a mandrel in a winding device. Precipitation of the solution and extraction of the fiber renders a tubular structure

containing helically oriented, interconnected transmural ingrowth channels in the tube wall suitable for use as a synthetic, small-diameter vascular graft prosthesis.

In another method, a paste comprising a polymer solution and an extractable filler is prepared and deposited in a layer onto a mandrel. An extractable fiber is also wound onto the mandrel. The paste and fiber can be applied to the mandrel either simultaneously or successively alternating between the paste and the fiber, until a desired thickness of the graft is achieved. Precipitation of the solution and extraction of the fiber produces the graft of the invention.

An alternative method for making the invention involves melt extrusion of a polymer containing strands of soluble fiber, with or without physically or chemically blowing a foamed tube.

With the foregoing in mind, it is a feature and advantage of the invention to provide a synthetic vascular graft wherein mechanical properties of the graft are matched with mechanical properties of the host vessel, thereby overcoming problems of compliance mismatch.

It is another feature and advantage of the invention to provide a synthetic vascular graft that contains helically oriented, interconnecting, transmural ingrowth channels.

It is a further feature and advantage of the invention to provide a method for producing a synthetic vascular graft that contains helically oriented, interconnecting, transmural ingrowth channels.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic drawing of a preferred method of producing the synthetic vascular graft of the invention.

Fig. 2 is a schematic drawing of an alternate method of producing the synthetic vascular graft of the invention.

Figs. 3a-3f are a series of perspective views of a mandrel from Fig. 2 as the method is carried out.

#### DEFINITIONS

The term "extractable fiber" means any polymeric or other fiber material that is soluble and extractable by a solvent other than the solvent used for the graft material. The fiber has a diameter ranging in size from 10 to 300 micrometers, more

preferably from 40 to 110 micrometers. The standard deviation of fibers used in this invention is typically less than 20 micrometers, more preferably less than 10 micrometers. Examples of suitable materials include alginate, gelatin, carbohydrates (sugar, dextrose, etc.), inorganic and organic salts. Water soluble fibers are suitable when water is the precipitation solvent and the fiber extractor.

The term "fiber extraction solvent" means any solvent capable of dissolving the extractable fiber without adversely affecting the graft structure. For example, water is a suitable fiber extraction solvent for water soluble fibers.

The term "non-extractable fiber" means any polymeric or other fiber material that is not extractable by the fiber extraction solvent. The fiber is either elastic or non-elastic non-degradable material, or a combination of elastic and non-elastic materials. Additionally, a reinforcing material that is either elastic or non-elastic, and is degradable *in vivo*, can be used in combination with the non-degradable material to provide initial strength to the graft. The non-extractable fiber typically has a diameter ranging in size from 10 to 100 micrometers. Examples of suitable non-elastic, non-degradable materials include polyethylene terephthalate (PET, Dacron) and polytetrafluoroethylene (PTFE). Examples of suitable elastic non-degradable materials include thermoplastic polyurethanes, e.g. M48, Pellethane (or clones), Biomeric (or clones), or any other biocompatible elastomer. Degradable polyurethanes can serve as degradable reinforcing fibers.

The term "precipitation solvent" means any solvent that is capable of precipitating the graft material from solution. The precipitation solvent and the graft material solvent are usually miscible in all proportions. Examples of suitable precipitation solvents include: water, ethanol, acetone, or combinations of any of these. The fiber extraction solvent and the precipitation solvent may or may not be the same solvent.

The term "graft material" means any polymeric or other material that can be dissolved in a suitable solvent and re-solidified after graft manufacture by air-drying, phase inversion, or combinations thereof. Examples of suitable graft materials include: thermoplastic elastomers including thermoplastic polyurethanes, e.g. Pellethane, Biomeric type polyurethanes, Chronoflex, and Hydrothane. In particular, a

polyurethane developed by Medtronic and described in U.S. Patent No. 4,873,308 is an example of a suitable graft material.

The term "graft material solvent" means any solvent capable of dissolving the graft material. Examples of suitable solvents for polyurethanes include: N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC), 1,4 dioxane, etc..

The term "graft material solution" means a solution of the graft material in the graft material solvent in concentrations ranging from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass.

The term "graft material paste" means an admixture consisting of a graft material solution and an extractable filler. The ratio of filler to polymer in the solution can range from 20:1 to 1:1; more typically from 10:1 to 5:1 (ratios by mass).

The term "chemical blowing agent" means any material that decomposes to form a gas, e.g.: CO<sub>2</sub> or N<sub>2</sub>, wherein the gas creates pores in the graft material.

Examples of chemical blowing agents include sodium bicarbonate and azodicarbonamides.

The term "physical blowing agent" means either a liquid or a gas that is introduced to molten graft material under pressure, wherein evaporation of the liquid or expansion of the gas creates bubbles that form pores in the graft material.

Examples of physical blowing agents include: chloro-fluoro carbons (e.g. freon), pentane, and hexane.

The term "extractable filler" means any polymeric or other filler material that is soluble and/or extractable by a solvent other than the solvent used for the graft material. The material is preferably spherical in shape with average diameters ranging in size from 10 to 300 micrometers, more preferably from 40 to 110 micrometers. The standard deviation of the diameters of the pores is typically less than 20 micrometers, more preferably less than 10 micrometers. Examples of suitable materials include protein beads, e.g. alginate, gelatin, carbohydrates (sugar, dextrose, etc.), inorganic and organic salts. Water soluble fillers are suitable when water is the precipitation solvent and the filler extractor.

## DETAILED DESCRIPTION OF THE

### PRESENTLY PREFERRED EMBODIMENTS

This invention is directed to an improved prosthetic vascular graft having a synthetic scaffold of transmural ingrowth channels which are characterized by an interconnected, helical orientation. A process of producing such channels in a synthetic scaffold can be achieved using an extractable fiber. The product and process are explained in detail below.

In order to promote ingrowth of connective tissue, it is important that mechanical properties of the graft are closely matched with mechanical properties of a host vessel, thereby overcoming problems of compliance mismatch. Although structure of blood vessels varies through a body, a "typical" artery consists of three distinct layers, each performing specific basic functions. An intima, consisting of an endothelium attached to a basement membrane, provides a non-thrombogenic blood contacting surface. A media contains smooth muscle cells (SMC's) as well as elastic and other intercellular connective and matrix materials, and supplies two other important properties to a blood vessel, namely compliance and contractility. In order to achieve these properties, tissues are oriented in a helical fashion in this medial layer. Another important property, namely structural integrity, is provided by an adventitia. A configuration of collagen fibers in the adventitia provides for "stiffening" of the vessel when subjected to high internal pressures, i.e. a decrease in compliance with increased strain.

The graft of the present invention has helically oriented, interconnected, transmural ingrowth channels that correspond to the helical arrangement of vascular tissues in the walls of natural arteries. The graft structure thereby creates an optimal strain environment that facilitates and encourages the development and maintenance of endothelial and smooth muscle cells in the vessel. By getting the smooth muscle cells to grow helically on the graft along the spiral channels, the graft acquires radial compliance and behaves like a real blood vessel. To achieve high porosity, the channels should be arranged at a very narrow angle, for example a 200 micron pitch. For larger wind angles, for example a 10 mm pitch, multiple fibers, all the same or a combination of soluble and reinforcing, can be wound around the graft to form corresponding channels. The pitch can be varied through the thickness of the wall by increasing or decreasing the pitch at a predefined rate as one builds up the graft wall, or alternating between two or more pitches in alternate layers. Preferably, the

channels have diameters in a range of 10-300  $\mu\text{m}$ , more preferably in a range of 40-110  $\mu\text{m}$ .

In designing the vascular prosthesis of the invention to result in formation of a neo-artery mimicking the properties of a natural vessel, material for the scaffold should have biostability, processability, availability, and desirable mechanical properties. The porous scaffold should provide high porosity for maximal cell ingrowth and minimal bulk compressibility (to allow for compressibility associated with contractility). The prosthesis should have structural integrity and viscoelastic properties similar to those observed for natural vessels. Furthermore, in order to minimize foreign body reaction and to encourage differential cell ingrowth, the scaffold materials should also exhibit long-term in-vivo stability. Examples of suitable scaffold materials include thermoplastic elastomers, particularly thermoplastic polyurethanes.

Because of their unique combination of physical, chemical and biocompatible properties, polyurethanes are preferred for use as the primary scaffold material in the vascular graft of the invention. Enzymatic hydrolysis, auto-oxidation, mineralization, and biologically induced environmental stress cracking of polyester- and polyetherurethanes have led manufacturers of medical polyurethanes to develop more specialized formulations to prevent these occurrences. Examples of particularly suitable medical polyurethanes include Pellethane, Biomer type polyurethanes, Chronoflex, and Hydrothane.

Helical channels are formed in the vascular graft by winding an extractable fiber into the graft material before the graft is set. Fibers suitable for forming the channels include alginate, gelatin, carbohydrates, inorganic and organic salts.

Selection of a suitable fiber material to create the channels requires careful consideration. The fibers can be round, flattened round, or elliptical. A flattened round fiber provides superior interconnectivity, but can be difficult to wind.

A multifactorial method (phase inversion/precipitation) can be used to solidify the scaffold material around the fibers. The solution properties of the fiber material are vital parameters in the process because the fiber material must be able to be solidified within the scaffold material and then extracted with a solvent while the scaffold material remains intact. The extractable fiber material should be non-soluble in the

solvent used to dissolve the scaffold material, readily soluble in the precipitation solution, processable into fibers, and non-toxic. Furthermore, the fiber material should have sufficient melt strength to be drawn down to desired dimensions (within about  $\pm 10 \mu\text{m}$  of the desired dimensions) and be strong enough in the fiber form to withstand winding. An additional, non-extractable fiber can be used in the graft of the invention to provide structural reinforcement.

The vascular graft of the present invention can be achieved by forming interconnecting, helically oriented channels in a wall of an elastomeric polymeric tubular structure using extractable fibers to form the channels. Suitable extractable fibers include those made from alginate, gelatin, carbohydrates, inorganic and organic salts. The fibers should have diameters of 10 to 300 micrometers, more preferably 40 to 110 micrometers. Several different methods can be used to produce these grafts.

The most preferred method for producing the graft of the present invention is a fiber winding and extraction technique. This method is illustrated in Fig. 1. The method involves assembling a mandrel 12 in a custom-designed winding device 10. The device 10 can be as simple as a personal computer 11 attached to a controller 13 which is further attached to two motors 15 and 17. One motor 15 drives translational movement of the fiber 14, while the other motor 17 drives rotation of the mandrel 12. The device 10 allows for accurate control over winding speed and position of the rotating mandrel 12 and translational movement of the fiber 14, thereby allowing for the accurate placement of wound fibers on the mandrel 12. The mandrel 12 has a diameter corresponding to a desired internal diameter of a resulting graft. The internal diameter of the graft is preferably between 1 mm and 20 mm, more preferably in the range of 2 to 6 mm for small diameter vessel replacement.

Once the winding device 10 is assembled, an extractable fiber 14 is coated with a solution 18 containing a biocompatible material. The extractable fiber 14 is made of alginate, gelatin, carbohydrates, or other soluble polymers, for example. The coating solution 18 includes a suitable graft material dissolved in a suitable graft material solvent. The coating solution may additionally contain soluble particulate fillers, such as microbeads, allowing for the creation of both spherical and channel-like porosity in the same graft. Suitable graft materials include thermoplastic elastomers, particularly thermoplastic polyurethanes, such as Pellethane, Biomer type

polyurethanes; Chronoflex, Hydrothane, Estane, Elast-Eon, Texin, Surethane, Corethane, Carbothane, Techoflex, Tecothane and Biospan. Suitable graft material solvents for polyurethanes include N-methyl pyrrolidone (NMP), N,N dimethyl diacetamide (DMAC); 1,4 dioxane; etc. Concentration of the graft material in the graft material solvent ranges from 1 to 40% by mass, more typically 5 to 30% by mass, usually 10 to 25% by mass. The concentration depends on various factors, including composition of the graft material, composition of the graft material solvent, and viscosity of the solution. After the fiber 14 is coated, the fiber 14 is wound onto the mandrel 12.

An additional non-extractable fiber 16 can also be wound onto the mandrel 12 for reinforcement. The non-extractable fiber 16 can be either elastic or non-elastic, or a combination of elastic and non-elastic materials. Additionally, a reinforcing material that is either elastic or non-elastic, and is degradable in vivo, can be used in combination with the non-degradable material to provide initial strength to the graft.

The reinforcement material that is degradable in vivo degrades as the graft is populated by ingrowing cells and accompanying extracellular matrix material.

Ingrowing material tends to stiffen the graft; therefore, a degradable fiber can be used to give initial strength to the graft without making the graft overly stiff after ingrowth.

The non-extractable fiber 16 typically has a diameter ranging in size from 10 to 100 micrometers. Examples of suitable non-elastic non-degradable materials include polyethylene terephthalate (PET, Dacron) and polytetrafluoroethylene (PTFE).

Examples of suitable elastic, non-degradable materials include thermoplastic polyurethanes, e.g., M48, Pellethane (or clones), Biomer (or clones), or any other biocompatible elastomer. Degradable polyurethanes can serve as degradable reinforcing fibers 16.

Tension on the extractable fibers 14 ensures "touching" of intersecting fiber strands, thereby ensuring communication between helical channels when the fibers 14 are extracted. The coating solution 18 is then solidified by phase precipitation, wherein the graft is immersed into a precipitation solvent, and/or by drying.

Examples of suitable precipitation solvents include water, ethanol, acetone, or combinations of any of these. The extractable fiber 14 is extracted by applying a fiber extraction solvent to produce channels in the space occupied by the fiber 14.

Another method for producing the graft of the invention is a melt extrusion technique with oriented fibers. In this method, a molten graft material containing chopped strands of extractable fibers is extruded from an extrusion die specially adapted to orient fibrous fillers in an extrudate. The extrusion results in a tubular structure having an internal diameter preferably between 1 mm and 20 mm, more preferably in a range of 2 to 6 mm for small diameter vessel replacement. The graft material can also contain additional, non-extractable fibers for reinforcement.

Physical and/or chemical blowing agents can be used to produce a foamed graft. In addition to choosing a suitable blowing agent, extrusion conditions must also be chosen carefully in order to avoid such obstacles as skin formation. There are various types of post-treatment for converting closed cell foams to open cell foams, which essentially entails removing a thin membrane between the cells or pores. One method involves heat treatment. By treating the closed cell foam in a controlled, elevated temperature environment, it is possible to melt the thin membrane without melting the rest of the material. The temperature depends on the graft material. Another method for converting closed cell foams to open cell foams is a mechanical method. By crushing the closed cell foam between rollers or a similar device, the thin membrane will rupture due to the pressure in the pore. A third method is another mechanical method wherein explosive gasses (e.g. stoichiometric ratios of O<sub>2</sub>/H<sub>2</sub>) are infiltrated into the pores. The cells are ruptured by ignition of these gasses. Yet another method is a chemical method whereby the foam is subjected to hydrolysis, thereby destroying the thinner membranes more rapidly than the thicker ribs defining the pores. Any of these methods can be used alone or in combination to produce open cell foams.

Yet another method for producing the graft of the invention is a particle and fiber extraction technique using a layered method. This method is illustrated in Figs. 2 and 3a-3f. In this method, a paste 30 is prepared from a graft material solution and an extractable filler, wherein the graft material solution comprises a graft material and a graft material solvent. As in the coating solution of the fiber winding and extraction technique, the suitable graft materials include thermoplastic elastomers, particularly thermoplastic polyurethanes, such as Pellethane, Biomer type polyurethanes, Chronoflex, and Hydrothane; and suitable graft material solvents include N-methyl pyrrolidone (NMP) and 1-methyl-2-pyrrolidinone. Suitable

materials for the extractable filler include protein beads, e.g. alginate, gelatin, carbohydrates, inorganic and organic salts.

A layer of the paste 30 is deposited onto a mandrel 32 having a diameter about equal to a desired internal diameter of a resulting graft. The internal diameter of the graft is preferably between 1 mm and 20 mm; more preferably in the range of 2 to 6 mm for small diameter vessel replacement. The paste 30 is pressed onto the mandrel 32 with a roller 34. An extractable fiber 36 is wound onto the paste layer. The extractable fiber 36 is made of alginate, gelatin, carbohydrates, inorganic or organic salts, for example. Additionally, a non-extractable fiber, as described in the fiber winding and extraction technique, can be wound onto the mandrel for reinforcement. Additional layers of the paste 30 alternating with additional layers of the wound extractable fiber 36, with or without a reinforcing fiber, are deposited onto the mandrel 32 until a desired graft thickness is achieved. The thickness of the paste 30 can vary from 0.1 to 5 mm, more preferably from 0.4 to 1.5 mm, depending on the diameter of the graft. The graft can be made with as few as two layers of the paste 30, with one layer of the wound extractable fiber 36 between the two paste layers.

Progressive stages of the mandrel 32 as the method is carried out are shown in Figs. 3a-3f. Fig. 3a shows a first layer of paste 38 rolled onto the mandrel 32. In Fig. 3b, a first fiber 40 is wound onto the first layer of paste 38. Fig. 3c shows a second layer of paste 42 covering the first layer of paste 38 and the first fiber 40. In Fig. 3d, a second fiber 44 is wound onto the second layer of paste 42. Fig. 3e shows a third layer of paste 46 covering the first two layers of paste 38 and 42 and the first two wound fibers 40 and 44. In Fig. 3f, a third fiber 48 is wound onto the third layer of paste 46.

The graft material solution is then precipitated by phase precipitation, wherein the graft is immersed into a precipitation solvent, and/or by drying. Examples of suitable precipitation solvents include water, ethanol, acetone, or combinations of any of these. The extractable fiber 36 and extractable filler are extracted, either simultaneously or consecutively, by applying a fiber extraction solvent to produce channels in the space occupied by the extractable fiber 36. A filler extraction solvent can be the same solvent as the fiber extraction solvent, and may vary only in

temperature, e.g. a cold water filler extraction solvent and a warm water fiber extraction solvent. The precipitation and extraction can be effected either simultaneously or consecutively.

A further method for producing the graft of the invention is a particle and fiber

5 extraction technique using a continuous method. Like the layered method, described above, the continuous method entails preparing a paste 30 from a graft material solution and an extractable filler, and layering the paste 30 and an extractable fiber 36 onto a mandrel 32, as shown in Fig. 2. However, in this method, the paste 30 is deposited onto the mandrel 32 simultaneously while the extractable fiber 36, with or without a reinforcing, non-extractable fiber, is wound onto the mandrel 32. As in the 10 layered method, the graft material solution is then precipitated and the extractable fiber 36 and extractable filler are extracted, either simultaneously or consecutively.

The above-described methods can also be used to produce other items, such as a biosynthetic, whole-root aortic valve prosthesis.

15 While the embodiments of the invention described herein are presently preferred, various modifications and improvements can be made without departing from the spirit and scope of the invention. The scope of the invention is indicated by the appended claims, and all changes that fall within the meaning and range of equivalents are intended to be embraced therein.

20

1. A method for producing a graft, comprising the steps of:

- (a) preparing a graft material solution;
- (b) adding an extractable fiber to the graft material solution;
- (c) precipitating the graft material solution;
- (d) extracting the extractable fiber; and
- (e) drying the graft.

2. The method of claim 1, wherein the extractable fiber is a polymer fiber.

3. The method of claim 1, wherein the extractable fiber is a collagen fiber.

4. The method of claim 1, wherein the extractable fiber is a synthetic fiber.

5. The method of claim 1, wherein the extractable fiber is a cellulose fiber.

6. The method of claim 1, wherein the extractable fiber is a protein fiber.

7. The method of claim 1, wherein the extractable fiber is a chitosan fiber.

8. The method of claim 1, wherein the extractable fiber is a polyvinyl alcohol fiber.

**WE CLAIM:**

1. A vascular graft prosthesis comprising:  
an elastomeric polymeric tubular structure having a wall; and  
interconnecting, helically oriented channels in the tube wall;  
wherein at least 75% of the channels have diameters within 10  $\mu\text{m}$  of one another.  
5
2. The vascular graft prosthesis of Claim 1 wherein the tubular structure has an internal diameter in a range of 1-20 mm.
- 10 3. The vascular graft prosthesis of Claim 1 wherein the tubular structure has an internal diameter in a range of 2-6 mm.
4. The vascular graft prosthesis of Claim 1 wherein the diameters of the channels are in a range of 10-300  $\mu\text{m}$ .
- 15 5. The vascular graft prosthesis of Claim 1 wherein the diameters of the channels are in a range of 40-110  $\mu\text{m}$ .
6. The vascular graft prosthesis of Claim 1 wherein the elastomeric polymeric tubular structure comprises polyurethane.  
20
7. The vascular graft prosthesis of Claim 1 wherein the elastomeric polymeric tubular structure comprises a segmented aliphatic polyurethane.
- 25 8. The vascular graft prosthesis of Claim 1 wherein the elastomeric polymeric tubular structure comprises a material selected from the group consisting of Pellethane, Chronoflex, Hydrothane, Estane, Elast-Eon, Texin, Biomar, Surethane, Corethane, Carbothane, Techoflex, Tecothane and Biospan.
- 30 9. The vascular graft prosthesis of Claim 1 further comprising reinforcing fibers in the elastomeric polymeric tubular structure.

10. The vascular graft prosthesis of Claim 9 wherein the reinforcing fibers comprise a non-elastic, non-degradable material.

11. The vascular graft prosthesis of Claim 9 wherein the reinforcing fibers 5 comprise an elastic, non-degradable material.

12. The reinforcing fibers of Claim 10 further comprising an elastic, non-degradable material.

10 13. The reinforcing fibers of Claim 10 further comprising a material degradable in vivo.

14. The reinforcing fibers of Claim 11 further comprising a material degradable in vivo.

15. The reinforcing fibers of Claim 12 further comprising a material degradable in vivo.

16. The vascular graft prosthesis of Claim 9 wherein the reinforcing fibers have 20 diameters in a range of 10 to 100 micrometers.

17. The vascular graft prosthesis of Claim 1 wherein at least 85% of the channels have diameters within 10  $\mu\text{m}$  of one another.

25 18. The vascular graft prosthesis of Claim 1 wherein at least 95% of the channels have diameters within 10  $\mu\text{m}$  of one another.

19. The vascular graft prosthesis of Claim 1 wherein substantially all of the channels have diameters within 10  $\mu\text{m}$  of one another.

30 20. An aortic valve prosthesis comprising:  
an elastomeric polymeric tubular structure having a wall; and

interconnecting, helically oriented channels in the tube wall;  
wherein at least 75% of the channels have diameters within 10  $\mu\text{m}$  of one another.

21. A method of making a prosthesis comprising the steps of:

5        assembling a mandrel in a winding device;  
coating an extractable fiber with a coating solution, wherein the coating  
solution comprises a graft material dissolved in a graft material solvent;  
winding the extractable fiber onto the mandrel;  
solidifying the coating solution; and  
extracting the fiber from the graft material.

10        22. The method of Claim 21 further comprising the step of winding a non-extractable, reinforcing fiber onto the mandrel simultaneously with the extractable fiber.

15        23. The method of Claim 21 wherein solidifying the coating solution is accomplished by precipitating the graft material in a precipitation solvent.

20        24. The method of Claim 21 wherein solidifying the coating solution is accomplished by drying the graft material solvent in the coating solution.

25        25. The method of Claim 21 wherein the mandrel has a diameter about equal to an internal diameter of the vascular graft prosthesis.

26. The method of Claim 21 wherein the diameter of the mandrel is in a range of 1-20 mm.

27. The method of Claim 21 wherein the diameter of the mandrel is in a range of 2-6 mm.

30        28. The method of Claim 21 wherein the fiber has a diameter in a range of 10-300  $\mu\text{m}$ .

29. The method of Claim 21 wherein the fiber has a diameter in a range of 40-110 µm.

5 30. The method of Claim 21 wherein the fiber comprises a polymer.

31. The method of Claim 21 wherein the graft material comprises a thermoplastic elastomer.

10 32. The method of Claim 21 wherein the graft material comprises a polyurethane.

33. The method of Claim 21 wherein the coating solution further comprises extractable beads.

15 34. An aortic valve prosthesis made according to the method of Claim 21.

35. A vascular graft prosthesis made according to the method of Claim 21.

20 36. A method of making a prosthesis comprising the steps of: extruding a molten polymer, wherein the polymer comprises chopped strands of soluble fibers; and annealing and reticulating the polymer to effect an open-cell structure.

25 37. The method of Claim 36 wherein a blowing agent is used to extrude the molten polymer.

38. The method of Claim 37 wherein the blowing agent comprises a physical blowing agent.

30 39. The method of Claim 37 wherein the blowing agent comprises a chemical blowing agent.

40. The method of Claim 37 wherein the blowing agent comprises physical and chemical blowing agents.

41. The method of Claim 36 wherein the polymer comprises a polyurethane.

5

42. The method of Claim 36 wherein the polymer further comprises reinforcing fibers.

43. An aortic valve prosthesis made according to the method of Claim 36.

10

44. A vascular graft prosthesis made according to the method of Claim 36.

15

45. A method of making a prosthesis comprising the steps of:  
preparing a paste comprising a graft material solution and an extractable filler;  
depositing a layer of the paste onto a mandrel, wherein the mandrel has a diameter  
about equal to a desired inside diameter of the vascular graft prosthesis;  
winding an extractable fiber onto the layer of paste;  
successively depositing additional layers of the paste and winding the  
extractable fiber onto each layer of the paste until a desired thickness of the vascular  
graft prosthesis is achieved;  
precipitating graft material from the graft material solution; and  
extracting the fiber from the graft material.

20

25

46. The method of Claim 45 wherein the diameter of the mandrel is in a range of

1-20 mm.

47. The method of Claim 45 wherein the diameter of the mandrel is in a range of  
2-6 mm.

30

48. The method of Claim 45 wherein the thickness of the vascular graft prosthesis  
is in a range of 0.1-5 mm.

49. The method of Claim 45 wherein the thickness of the vascular graft prosthesis is in a range of 0.4-1.5 mm.

50. The method of Claim 45 wherein the fiber has a diameter in a range of 10-300  $\mu\text{m}$ .

51. The method of Claim 45 wherein the fiber has a diameter in a range of 40-110  $\mu\text{m}$ .

10 52. The method of Claim 45 wherein the fiber comprises a polymer.

53. The method of Claim 45 wherein the graft material comprises a thermoplastic elastomer.

15 54. The method of Claim 45 wherein the graft material comprises a polyurethane.

55. The method of Claim 45 further comprising the step of winding a non-extractable, reinforcing fiber onto the paste simultaneously with the winding of the extractable fiber.

20 56. The method of Claim 45 wherein the graft material is precipitated from the graft material solution and the fiber is extracted from the graft material simultaneously.

25 57. An aortic valve prosthesis made according to the method of Claim 45.

58. A vascular graft prosthesis made according to the method of Claim 45.

30 59. A method of making a prosthesis comprising the steps of: preparing a paste comprising a graft material solution and an extractable filler; depositing a layer of the paste onto a mandrel, and simultaneously winding an extractable fiber onto the mandrel, until a desired thickness of the vascular graft

prosthesis is achieved, wherein the mandrel has a diameter about equal to a desired inside diameter of the vascular graft prosthesis;

precipitating graft material from the graft material solution; and  
extracting the fiber from the graft material.

5

60. The method of Claim 59 wherein the diameter of the mandrel is in a range of 1-20 mm.

10 61. The method of Claim 59 wherein the diameter of the mandrel is in a range of 2-6 mm.

15 62. The method of Claim 59 wherein the thickness of the vascular graft prosthesis is in a range of 0.1-5 mm.

63. The method of Claim 59 wherein the thickness of the vascular graft prosthesis is in a range of 0.4-1.5 mm.

20 64. The method of Claim 59 wherein the fiber has a diameter in a range of 10-300  $\mu\text{m}$ .

65. The method of Claim 59 wherein the fiber has a diameter in a range of 40-110  $\mu\text{m}$ .

25 66. The method of Claim 59 wherein the fiber comprises a polymer.

67. The method of Claim 59 wherein the graft material comprises a thermoplastic elastomer.

30 68. The method of Claim 59 wherein the graft material comprises a polyurethane.

69. The method of Claim 59 further comprising the step of winding a non-extractable, reinforcing fiber onto the paste simultaneously with the depositing of the layers of paste and the winding of the extractable fiber.

5 70. The method of Claim 59 wherein the graft material is precipitated from the graft material solution and the fiber is extracted from the graft material simultaneously.

10 71. An aortic valve prosthesis made according to the method of Claim 59.

72. A vascular graft prosthesis made according to the method of Claim 59.

1 / 3




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2 / 3










FIG. 2

SUBSTITUTE SHEET (RULE 26)

37/3


**FIG. 3a****FIG. 3b****FIG. 3c****FIG. 3d****FIG. 3e****FIG. 3f**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> :	A61F 2/06, A61L 27/00, B29C 53/58, 47/00	A3	(11) International Publication Number:	WO 00/30564
(21) International Application Number:	PCT/US99/27504		(43) International Publication Date:	2 June 2000 (02.06.00)
(22) International Filing Date:	19 November 1999 (19.11.99)		(81) Designated States:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(30) Priority Data:	60/109,526 09/434,071	23 November 1998 (23.11.98) 5 November 1999 (05.11.99)	US	
(71) Applicant:	MEDTRONIC, INC. [US/US]; 7000 Central Avenue NE, Minneapolis, MN 55432 (US).		(88) Date of publication of the international search report:	16 November 2000 (16.11.00)
(72) Inventors:	ZILLA, Peter, Paul; 14 Dal Road, 8005 Camps Bay (ZA). BEZUIDENHOUT, Deon; 2 Liebenhoff, Merriman Avenue, 7600 Stellenbosch (ZA).		Published	With international search report.
(74) Agents:	DUTHLER, Reed, A. et al.; Medtronic, Inc., 7000 Central Avenue NE, Minneapolis, MN 55432 (US).			

## (54) Title: POROUS SYNTHETIC VASCULAR GRAFTS WITH ORIENTED INGROWTH CHANNELS



## (57) Abstract

A vascular prosthesis is constructed from a structure having interconnected, helically oriented channel-porosity to allow oriented ingrowth of connective tissue into a wall of the prosthesis. The prosthesis can have a small internal diameter of 6 mm or less. Several different methods can be used to produce the prosthesis, including a fiber winding and extraction technique, a melt extrusion technique, and a particle and fiber extraction technique using either a layered method or a continuous method. Furthermore, mechanical properties of the prosthesis are matched with mechanical properties of the host vessel, thereby overcoming problems of compliance mismatch.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	NL	Netherlands	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Démocratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/27504

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>	
IPC 7 A61F2/06	A61L27/00 B29C53/58 B29C47/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61F B29C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 26731 A (atrium MEDICAL CORP) 25 June 1998 (1998-06-25) page 2, line 23 - line 32; figures; example A page 8, line 7 - line 24 page 11, line 21 - page 12, line 21 page 1, line 14 - line 22 page 14, line 15 - line 27 ---	1-3,6,9, 20
A	US 4 306 318 A (MANO HIROSHI ET AL) 22 December 1981 (1981-12-22) column 2, line 34 - line 60; claims; figures; example 1 ---	1-3,6,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

- \* Special categories of cited documents :
- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

1 September 2000

Date of mailing of the international search report

15.09.2000

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentiaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Wallene, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/27504

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 824 050 A (KARWOSKI THEODORE ET AL) 20 October 1998 (1998-10-20) column 2, line 5 - line 18; claim 9; examples 1-3 column 1, line 32 - line 40 ---	1,6,9,20
A	WO 97 24081 A (LOVE CHARLES S ;RAMUS MEDICAL TECHNOLOGIES (US)) 10 July 1997 (1997-07-10) page 8, line 5 - line 10 page 12, line 21 -page 13, line 36; figures ---	20
A	US 5 061 276 A (TU ROGER ET AL) 29 October 1991 (1991-10-29) the whole document ---	20
A	US 4 834 755 A (SILVESTRINI THOMAS A ET AL) 30 May 1989 (1989-05-30) the whole document ---	20
A	EP 0 256 748 A (BAXTER TRAVENOL LAB) 24 February 1988 (1988-02-24) the whole document ---	21-72
A	GB 2 117 246 A (J AND P COATS LIMITED) 12 October 1983 (1983-10-12) claims; figures ---	21-72
A	EP 0 269 449 A (BAXTER TRAVENOL LAB) 1 June 1988 (1988-06-01) page 5, line 23 - line 41; claim 12 ---	21-72
A	US 5 688 836 A (YAMAMOTO KATSUTOSHI ET AL) 18 November 1997 (1997-11-18) example 1 -----	21-72

International application No.  
PCT/US 99/27504

## INTERNATIONAL SEARCH REPORT

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19

A vascular graft prosthesis comprising a polymer tubular structure having interconnecting, helically oriented channels in the tubular wall

2. Claim : 20

An aortic valve prosthesis comprising a polymer wall with interconnecting, helically oriented channels in the wall

3. Claims: 21-35

A method of making a prosthesis comprising a mandrel, coating a fiber with a solution which comprises a graft material and winding the fiber onto the mandrel; solidifying the coating solution and extracting the fiber from the graft material

4. Claims: 36-44

A method of making a prosthesis by extruding molten polymer comprised of chopped strands of soluble fibers and annealing and reticulating the polymer

5. Claims: 45-58,59-72

A method of making a prosthesis by preparing a paste comprising a graft material and a filler; depositing a layer of the paste onto the mandrel; winding the fiber onto the paste; repeating the process until the desired thickness of the graft is achieved; precipitating graft material from the solution and extracting the fiber from the graft material

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 99/27504

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9826731 A	25-06-1998	US 6010529 A US 5897587 A US 5824050 A AU 5898498 A EP 0971643 A US 6042666 A	04-01-2000 27-04-1999 20-10-1998 15-07-1998 19-01-2000 28-03-2000
US 4306318 A	22-12-1981	JP 1313019 C JP 55052755 A JP 60037734 B AU 527117 B AU 5169379 A BE 879355 A CA 1143105 A DE 2941279 A FR 2438472 A GB 2033233 A,B IT 1164833 B NL 7907531 A,B, SE 7908447 A US RE31618 E	28-04-1986 17-04-1980 28-08-1985 17-02-1983 17-04-1980 01-02-1980 22-03-1983 17-04-1980 09-05-1980 21-05-1980 15-04-1987 15-04-1980 13-04-1980 03-07-1984
US 5824050 A	20-10-1998	AU 5898498 A EP 0971643 A WO 9826731 A US 6042666 A	15-07-1998 19-01-2000 25-06-1998 28-03-2000
WO 9724081 A	10-07-1997	US 5865723 A AU 720362 B AU 1569297 A CA 2240989 A EP 0874603 A JP 2000502586 T	02-02-1999 01-06-2000 28-07-1997 10-07-1997 04-11-1998 07-03-2000
US 5061276 A	29-10-1991	US 4816339 A CA 1302897 A EP 0293090 A JP 1046468 A	28-03-1989 09-06-1992 30-11-1988 20-02-1989
US 4834755 A	30-05-1989	US 4610688 A AT 21816 T AU 554461 B AU 2636584 A CA 1220601 A DE 3460597 D DK 176984 A EP 0122744 A ES 286681 Y IE 55194 B IL 71426 A JP 1375239 C JP 59194738 A JP 61040420 B KR 8601954 B MX 159168 A ZA 8402473 A	09-09-1986 15-09-1986 21-08-1986 11-10-1984 21-04-1987 09-10-1986 05-10-1984 24-10-1984 01-12-1986 20-06-1990 30-06-1988 22-04-1987 05-11-1984 09-09-1986 05-11-1986 26-04-1989 27-11-1985
EP 0256748 A	24-02-1988	JP 63041544 A	22-02-1988

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 99/27504

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2117246	A 12-10-1983	NONE	
EP 0269449	A 01-06-1988	JP 63226361 A	21-09-1988
US 5688836	A 18-11-1997	DE 69327041 D DE 69327041 T EP 0613921 A WO 9403531 A	23-12-1999 13-04-2000 07-09-1994 17-02-1994